Dual mechanism of action of nicorandil on rabbit corpus cavernosal smooth muscle tone

被引:0
作者
GC Hsieh
T Kolasa
JP Sullivan
JD Brioni
机构
[1] Neurological and Urological Diseases Research,
[2] Abbott Laboratories,undefined
来源
International Journal of Impotence Research | 2001年 / 13卷
关键词
nicorandil; erectile dysfunction; K; channel; guanylate cyclase;
D O I
暂无
中图分类号
学科分类号
摘要
The potential of ATP-sensitive potassium channel openers (KCOs) for the treatment of male erectile dysfunction has recently been suggested based on positive clinical outcomes following intra-cavernosal administration of pinacidil. Agents that increase the levels of cGMP via elevation of nitric oxide (NO) nitroglycerin, for example, are also effective in improving erectile function preclinically and clinically. The aim of the present study was to determine the effects and mechanism of the action of nicorandil on rabbit corpus cavernosum. The in vitro regulation of smooth muscle tone was assessed in isolated cavernosal tissues pre-contracted with phenyl-ephrine. Nicorandil, but not its major metabolite, relaxed phenylephrine-precontracted cavernosum smooth muscle with an EC50 of 15 μM. The effects of nicorandil were only partially reversed by the KATP channel blocker glyburide (10 μM) or by a soluble guanylate cyclase (sGC) inhibitor 1H-[1,2,4] oxadiazole [4,3-a] quinoxalin-1-one (ODQ, 3 μM). However, a combination of ODQ and glyburide completely blocked the relaxant effects of nicorandil. The results of the present study indicate that nicorandil can relax rabbit cavernosal tissue in vitro via a mechanism that involves activation of KATP channels and stimulation of soluble guanylate cyclase.
引用
收藏
页码:240 / 246
页数:6
相关论文
共 60 条
  • [21] Giraldi F(1995)Differential relaxation of human corpus cavernosum smooth muscle by potassium openers: evidence that relaxation is both agonist dependent and altered by diabetes melitus. Mol Pharmacol 48 184-350
  • [22] Wagner KE(1999)The efficacy, safety, and tolerability of intracavernosal PNU-83587 in the treatment of erectile dysfunction. Biochim Biophys Acta 1411 334-14758
  • [23] Holmquist M(1999)Potassium channel openers: pharmacological and clinical aspects. Proc Natl Acad Sci USA 96 14753-4198
  • [24] Andersson H(2000)Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4, 3-a]quinoxalin-1-one. Biochemistry 39 4191-S21
  • [25] Fovaeus DG(1992)Guanylate cyclase and the NO/cGMP signaling pathway. J Cardiovasc Pharmacol 20 (Suppl 3): S17-undefined
  • [26] Hedlund HS(undefined)A molecular basis for nitric oxide sensing by soluble guanylate cyclase. undefined undefined undefined-undefined
  • [27] Moon JJ(undefined)Interaction of soluble guanylate cyclase with YC-1: kinetic and resonance Raman studies. undefined undefined undefined-undefined
  • [28] Byun M(undefined)Differential effects of nitrovasolidators, K channel openers and nicorandil on large and small coronary arteries in conscious dogs. undefined undefined undefined-undefined
  • [29] Kim BR(undefined)undefined undefined undefined undefined-undefined
  • [30] Goldschmidt WH(undefined)undefined undefined undefined undefined-undefined